Itamar Medical has entered into a distribution agreement with Politec Saúde and Smart Medical for the distribution of the WatchPAT in Brazil and Chile respectively.
Itamar said its both products are being used for research purposes in various university hospitals.
The EndoPAT is deigned for investigating mainly cardiovascular disease, biological, behavioral, diabetes, environmental, occupational and social behavior.
Itamar Medical CEO and president Dov Rubin said Brazil provides great potential for WatchPAT home testing to surpass in-lab sleep labs and greater cost savings for consumers.
"We expect to see similar success for EndoPAT," Rubin said.
